Thrombolex announces 510(k) clearance of Bashir catheter systems for thromboembolic disorders

Updated: May 21, 2019

Thrombolex has announced that the US Food and Drug Administration (FDA) has cleared the Bashir Endovascular Catheter (BEC) for the controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature, and the Bashir N-X Endovascular Catheter (BEC N-X) for the controlled and selective infusion of physician-specified fluids into the peripheral and pulmonary artery vasculature. The company has also received FDA clearance to begin an early feasibility study evaluating the Bashir platform for treatment of pulmonary embolism. To read more please click the link below.


https://venousnews.com/thrombolex-fda-clearance-bashir-systems/

66 views